Team | Year | Pos | G | IP | PO | A | E | Fld % | RF | Eff | ZR |
---|---|---|---|---|---|---|---|---|---|---|---|
Sao Paulo - SABL
SPO - SABL
|
2041 | C | 8 | 55.2 | 51 | 0 | 1 | .981 | 8.25 | .000 | -3.76 |
Sao Paulo - SABL
SPO - SABL
|
2041 | 2B | 26 | 187.2 | 58 | 29 | 2 | .978 | 4.17 | .686 | -4.95 |
Sao Paulo - SABL
SPO - SABL
|
2041 | CF | 2 | 16.0 | 5 | 0 | 0 | 1.000 | 2.81 | .722 | -1.61 |
Traverse City - SNL (R)
TRV - SNL (R)
|
2040 | C | 1 | 3.0 | 0 | 0 | 0 | .000 | 0.00 | .000 | 0.01 |
Traverse City - SNL (R)
TRV - SNL (R)
|
2040 | 2B | 8 | 29.2 | 4 | 9 | 1 | .929 | 3.94 | .858 | -0.66 |
Pfizer - HSAS (HS)
PFZ - HSAS (HS)
|
2037 | 2B | 17 | 137.0 | 32 | 30 | 4 | .939 | 4.07 | .900 | -2.13 |
Pfizer - HSAS (HS)
PFZ - HSAS (HS)
|
2036 | 1B | 1 | 1.0 | 1 | 0 | 0 | 1.000 | 9.00 | .000 | 0.00 |
Pfizer - HSAS (HS)
PFZ - HSAS (HS)
|
2036 | 2B | 2 | 10.0 | 3 | 3 | 0 | 1.000 | 5.40 | 1.078 | 0.06 |
Pfizer - HSAS (HS)
PFZ - HSAS (HS)
|
2035 | 2B | 2 | 7.0 | 0 | 0 | 0 | .000 | 0.00 | .000 | 0.00 |
Pfizer - HSAS (HS)
PFZ - HSAS (HS)
|
2035 | RF | 2 | 17.0 | 6 | 0 | 0 | 1.000 | 3.18 | 1.055 | 0.19 |
Pfizer - IFC
PFZ - IFC
|
2034 | 2B | 2 | 14.0 | 7 | 3 | 0 | 1.000 | 6.43 | 1.107 | 0.18 |
Pfizer - IFC
PFZ - IFC
|
2034 | CF | 13 | 114.2 | 33 | 1 | 3 | .919 | 2.67 | .915 | -2.47 |
Pfizer - IFC
PFZ - IFC
|
2034 | RF | 4 | 26.0 | 7 | 0 | 0 | 1.000 | 2.42 | 1.077 | 0.71 |
Total | C | 9 | 58.2 | 51 | 0 | 1 | -3.75 | ||||
Total | 1B | 1 | 1.0 | 1 | 0 | 0 | 0.00 | ||||
Total | 2B | 57 | 385.1 | 104 | 74 | 7 | -7.50 | ||||
Total | CF | 15 | 130.2 | 38 | 1 | 3 | -4.08 | ||||
Total | RF | 6 | 43.0 | 13 | 0 | 0 | 0.90 |